Last reviewed · How we verify
AL8326 tablets
AL8326 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to alter gene expression and induce anti-tumor effects.
AL8326 is a selective inhibitor of histone deacetylase (HDAC) that promotes acetylation of histones and non-histone proteins to alter gene expression and induce anti-tumor effects. Used for Peripheral T-cell lymphoma (PTCL), Cutaneous T-cell lymphoma (CTCL).
At a glance
| Generic name | AL8326 tablets |
|---|---|
| Also known as | AL8326 |
| Sponsor | Advenchen Laboratories Nanjing Ltd. |
| Drug class | Histone deacetylase (HDAC) inhibitor |
| Target | Histone deacetylase (HDAC) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting HDAC enzymes, AL8326 increases acetylation of histone proteins, leading to more open chromatin structure and altered transcription of genes involved in cell cycle arrest and apoptosis. This mechanism is particularly relevant in hematologic malignancies where HDAC inhibition can restore expression of tumor suppressor genes and promote differentiation or death of cancer cells.
Approved indications
- Peripheral T-cell lymphoma (PTCL)
- Cutaneous T-cell lymphoma (CTCL)
Common side effects
- Thrombocytopenia
- Anemia
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- A Phase I/IIa Study of AL8326 Combined With Toripalimab in the Treatment of Advanced Solid Tumors. (PHASE1, PHASE2)
- A Study of AL8326 in Non-Small Cell Lung Cancer (PHASE1)
- A Phase IIII Study of AL8326 in Small Cell Lung Cancer (PHASE3)
- A Study of Diet Influence of AL8326 in Chinese Healthy Adult Subjects (PHASE1)
- A Phase I Study of AL8326 in Advanced Solid Tumor (PHASE1)
- A Phase Ib / IIA Study of AL8326 in Small Cell Lung Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AL8326 tablets CI brief — competitive landscape report
- AL8326 tablets updates RSS · CI watch RSS
- Advenchen Laboratories Nanjing Ltd. portfolio CI